LT2599778T - Diamido junginiai, pasižymintys muskarininiam receptoriui antagonistiniu ir beta 2 adrenerginiam receptoriui agonistiniu aktyvumu - Google Patents

Diamido junginiai, pasižymintys muskarininiam receptoriui antagonistiniu ir beta 2 adrenerginiam receptoriui agonistiniu aktyvumu

Info

Publication number: LT2599778T
Authority: LT; Lithuania
Prior art keywords: beta; agonist activity; diamide compounds; receptor antagonist; receptor agonist
Prior art date: 2009-04-23

Application number

LTEP13151470.5T

Other languages

English (en)

Inventor

Adam Hughes

Daniel Byun

Yan Chen

Melissa Fleury

John Jacobsen

Eric Strangeland

Richard Wilson

Rose Yen

Original Assignee

Theravance Respiratory Company, Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-23

Filing date

2010-04-16

Publication date

2017-08-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42272140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2599778(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-04-16 Application filed by Theravance Respiratory Company, Llc filed Critical Theravance Respiratory Company, Llc

2017-08-25 Publication of LT2599778T publication Critical patent/LT2599778T/lt

Links

102100039705 Beta-2 adrenergic receptor Human genes 0.000 title 1
229940121948 Muscarinic receptor antagonist Drugs 0.000 title 1
239000000048 adrenergic agonist Substances 0.000 title 1
229940126157 adrenergic receptor agonist Drugs 0.000 title 1
108010014499 beta-2 Adrenergic Receptors Proteins 0.000 title 1
150000001470 diamides Chemical class 0.000 title 1
230000000694 effects Effects 0.000 title 1
239000003149 muscarinic antagonist Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Hydrogenated Pyridines (AREA)

LTEP13151470.5T 2009-04-23 2010-04-16 Diamido junginiai, pasižymintys muskarininiam receptoriui antagonistiniu ir beta 2 adrenerginiam receptoriui agonistiniu aktyvumu LT2599778T (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US17203909P	2009-04-23	2009-04-23

Publications (1)

Publication Number	Publication Date
LT2599778T true LT2599778T (lt)	2017-08-25

Family

ID=42272140

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP17164740.7T LT3210981T (lt)	2009-04-23	2010-04-16	Diamidu junginiai, pasižymintys muskarininių receptorių atžvilgiu antagonistiniu ir beta 2 adrenerginių receptorių atžvilgiu agonistiniu aktyvumu
LTEP13151470.5T LT2599778T (lt)	2009-04-23	2010-04-16	Diamido junginiai, pasižymintys muskarininiam receptoriui antagonistiniu ir beta 2 adrenerginiam receptoriui agonistiniu aktyvumu

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTEP17164740.7T LT3210981T (lt)	2009-04-23	2010-04-16	Diamidu junginiai, pasižymintys muskarininių receptorių atžvilgiu antagonistiniu ir beta 2 adrenerginių receptorių atžvilgiu agonistiniu aktyvumu

Country Status (31)

Country	Link
US (14)	US8138345B2 (lt)
EP (3)	EP2599778B1 (lt)
JP (3)	JP5671006B2 (lt)
KR (1)	KR101769061B1 (lt)
CN (2)	CN102405218B (lt)
AR (1)	AR076412A1 (lt)
AU (1)	AU2010239522B2 (lt)
BR (1)	BRPI1014877B8 (lt)
CA (1)	CA2758505C (lt)
CL (1)	CL2011002637A1 (lt)
CO (1)	CO6440584A2 (lt)
CY (2)	CY1119008T1 (lt)
DK (3)	DK2421849T3 (lt)
ES (3)	ES2417339T3 (lt)
HR (3)	HRP20130468T1 (lt)
HU (2)	HUE042975T2 (lt)
IL (1)	IL215554A (lt)
LT (2)	LT3210981T (lt)
MX (1)	MX2011011156A (lt)
MY (1)	MY158339A (lt)
NZ (1)	NZ595850A (lt)
PL (3)	PL3210981T3 (lt)
PT (3)	PT2599778T (lt)
RU (2)	RU2543716C2 (lt)
SG (1)	SG175330A1 (lt)
SI (3)	SI2421849T1 (lt)
SM (3)	SMT201900168T1 (lt)
TR (1)	TR201903556T4 (lt)
TW (2)	TWI513693B (lt)
WO (1)	WO2010123766A1 (lt)
ZA (1)	ZA201107743B (lt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2599778T (pt)	2009-04-23	2017-06-06	Theravance Respiratory Co Llc	Compostos de diamida possuindo actividade antagonista do receptor muscarínico e agonista do receptor adrenérgico beta 2
ITRM20110083U1 (it)	2010-05-13	2011-11-14	De La Cruz Jose Antonio Freire	Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en)	2010-05-13	2011-11-16	Almirall, S.A.	New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
AR083115A1 (es) *	2010-09-30	2013-01-30	Theravance Inc	Sales oxalato cristalinas de un compuesto diamida
HRP20151317T1 (hr)	2011-06-10	2016-01-01	Chiesi Farmaceutici S.P.A.	Spojevi koji pokazuju aktivnost prema antagonistima muskarinskog receptora i beta2 adrenergiäśnog receptora
RU2606121C2 (ru)	2011-06-10	2017-01-10	КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.	Соединения, обладающие антагонистической активностью в отношении мускариновых рецепторов и агонистической активностью в отношении бета2-адренорецепторов
EP2592078A1 (en)	2011-11-11	2013-05-15	Almirall, S.A.	New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP3345904B1 (en)	2012-12-06	2020-07-29	Chiesi Farmaceutici S.p.A.	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
KR102156441B1 (ko)	2012-12-06	2020-09-17	키에시 파르마슈티시 엣스. 피. 에이.	무스카린성 수용체 길항제 및 베타2 아드레날린성 수용체 효능제 활성을 가지는 화합물
AU2013360866A1 (en)	2012-12-18	2015-07-02	Almirall, S.A.	New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activity
TWI643853B (zh)	2013-02-27	2018-12-11	阿爾米雷爾有限公司	同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh)	2013-07-25	2015-05-16	Almirall Sa	含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh)	2013-07-25	2018-11-21	阿爾米雷爾有限公司	具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
CN104030933A (zh) *	2014-05-16	2014-09-10	烟台恒迪克能源科技有限公司	一种β-异烷醇基氨基戊酸环己胺的合成方法
TW201617343A (zh)	2014-09-26	2016-05-16	阿爾米雷爾有限公司	具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
TWI703138B (zh)	2015-02-12	2020-09-01	義大利商吉斯藥品公司	具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
CN107074816B (zh) *	2015-03-27	2020-07-17	四川海思科制药有限公司	一种杂环衍生物及其制备方法和在医药上的用途
TW201702225A (zh) *	2015-05-14	2017-01-16	Sichuan Haisco Pharmaceutical Co Ltd	具有β２受體激動及Ｍ受體拮抗活性的含氮雜螺環衍生物及其在醫藥上的用途
CN107108502A (zh) *	2015-05-14	2017-08-29	四川海思科制药有限公司	具有β2受体激动及M受体拮抗活性的联苯衍生物及其在医药上的用途
AR104828A1 (es)	2015-06-01	2017-08-16	Chiesi Farm Spa	COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
WO2017093208A1 (en)	2015-12-03	2017-06-08	Chiesi Farmaceutici S.P.A.	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CN107849019A (zh) *	2016-01-22	2018-03-27	四川海思科制药有限公司	一种氮杂环酰胺衍生物及其制备方法和在医药上的用途
EP3484879B1 (en)	2016-07-13	2020-12-30	Chiesi Farmaceutici S.p.A.	Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
JP6963616B2 (ja)	2016-12-14	2021-11-10	ベイジンショウバイファーマシューティカルカンパニー，リミティッド	４級アンモニウム塩構造を有する二官能性化合物
US11065235B2 (en)	2017-05-19	2021-07-20	Council Of Scientific & Industrial Research	Substituted methanopyrido [2, 1-a] isoindolones as mAChR modulators for treating various associated pathophysiological conditions and process for preparation thereof
WO2020047225A1 (en)	2018-08-30	2020-03-05	Theravance Biopharma R&D Ip, Llc	Methods for treating chronic obstructive pulmonary disease
US10562930B1 (en) *	2018-08-31	2020-02-18	Praxis Precision Medicines, Inc.	Salts and crystal forms of GABAA positive allosteric modulator
CN117924216A (zh) *	2024-01-12	2024-04-26	王叔和生物医药(武汉)有限公司	一种1-哌啶丙酸的合成方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6541669B1 (en)	1998-06-08	2003-04-01	Theravance, Inc.	β2-adrenergic receptor agonists
MXPA02005596A (es) *	1999-12-07	2004-09-10	Theravance Inc	Derivados de carbamato con actividad antagonista para el rerceptor muscarinico.
UA73543C2 (uk) *	1999-12-07	2005-08-15	Тераванс, Інк.	Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
US6858596B2 (en)	2000-08-05	2005-02-22	Smithkline Beecham Corporation	Formulation containing anti-inflammatory androstane derivative
US6759398B2 (en)	2000-08-05	2004-07-06	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative
US6750210B2 (en)	2000-08-05	2004-06-15	Smithkline Beecham Corporation	Formulation containing novel anti-inflammatory androstane derivative
EP2067784A3 (en)	2000-08-05	2012-08-22	Glaxo Group Limited	17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivatives as anti-inflammatory agents
UA77656C2 (en)	2001-04-07	2007-01-15	Glaxo Group Ltd	S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
WO2003049518A1 (fr) *	2001-12-04	2003-06-12	Tokyo R & D Co., Ltd.	Alimentation de courant
PE20040950A1 (es) *	2003-02-14	2005-01-01	Theravance Inc	DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
CN101239969B (zh) *	2003-02-14	2011-07-20	施万制药	联苯衍生物
ES2289691T3 (es)	2004-01-22	2008-02-01	Pfizer, Inc.	Derivados de sulfonamida para el tratamiento de enfermedades.
WO2005080375A1 (en) *	2004-02-13	2005-09-01	Theravance, Inc.	Crystalline form of a biphenyl compound
WO2005092861A1 (en)	2004-03-11	2005-10-06	Pfizer Limited	Quinolinone derivatives pharmaceutical compositions containing them and their use
TWI341836B (en)	2004-03-11	2011-05-11	Theravance Inc	Biphenyl compounds useful as muscarinic receptor antagonists
US7307076B2 (en)	2004-05-13	2007-12-11	Boehringer Ingelheim International Gmbh	Beta agonists for the treatment of respiratory diseases
WO2006023460A2 (en) *	2004-08-16	2006-03-02	Theravance, Inc.	COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
TWI374883B (en) *	2004-08-16	2012-10-21	Theravance Inc	Crystalline form of a biphenyl compound
WO2006023457A1 (en) *	2004-08-16	2006-03-02	Theravance, Inc.	COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
AU2006337928B2 (en)	2006-02-08	2012-12-20	Fuji Oil Company, Limited	Edible products with low content of saturated and trans unsaturated fats
GB0602778D0 (en) *	2006-02-10	2006-03-22	Glaxo Group Ltd	Novel compound
TW200811104A (en) *	2006-04-25	2008-03-01	Theravance Inc	Crystalline forms of a dimethylphenyl compound
TW200811105A (en) *	2006-04-25	2008-03-01	Theravance Inc	Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2008096129A1 (en)	2007-02-07	2008-08-14	Argenta Discovery Ltd	Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
RU2539979C2 (ru)	2008-07-25	2015-01-27	Вайтаи Фармасьютиклз, Инк.	Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1
PT2599778T (pt)	2009-04-23	2017-06-06	Theravance Respiratory Co Llc	Compostos de diamida possuindo actividade antagonista do receptor muscarínico e agonista do receptor adrenérgico beta 2

2010
- 2010-04-16 PT PT131514705T patent/PT2599778T/pt unknown
- 2010-04-16 PL PL17164740T patent/PL3210981T3/pl unknown
- 2010-04-16 CN CN201080017581.XA patent/CN102405218B/zh not_active Expired - Fee Related
- 2010-04-16 BR BRPI1014877A patent/BRPI1014877B8/pt not_active IP Right Cessation
- 2010-04-16 WO PCT/US2010/031356 patent/WO2010123766A1/en not_active Ceased
- 2010-04-16 DK DK10715058.3T patent/DK2421849T3/da active
- 2010-04-16 SI SI201030228T patent/SI2421849T1/sl unknown
- 2010-04-16 PT PT17164740T patent/PT3210981T/pt unknown
- 2010-04-16 MY MYPI2011004779A patent/MY158339A/en unknown
- 2010-04-16 US US12/761,532 patent/US8138345B2/en not_active Expired - Fee Related
- 2010-04-16 HU HUE17164740A patent/HUE042975T2/hu unknown
- 2010-04-16 LT LTEP17164740.7T patent/LT3210981T/lt unknown
- 2010-04-16 SI SI201031866T patent/SI3210981T1/sl unknown
- 2010-04-16 MX MX2011011156A patent/MX2011011156A/es active IP Right Grant
- 2010-04-16 HR HRP20130468AT patent/HRP20130468T1/hr unknown
- 2010-04-16 DK DK17164740.7T patent/DK3210981T3/en active
- 2010-04-16 TR TR2019/03556T patent/TR201903556T4/tr unknown
- 2010-04-16 ES ES10715058T patent/ES2417339T3/es active Active
- 2010-04-16 ES ES17164740T patent/ES2715965T3/es active Active
- 2010-04-16 CN CN201410175377.0A patent/CN103936716B/zh not_active Expired - Fee Related
- 2010-04-16 DK DK13151470.5T patent/DK2599778T3/en active
- 2010-04-16 CA CA2758505A patent/CA2758505C/en not_active Expired - Fee Related
- 2010-04-16 KR KR1020117027797A patent/KR101769061B1/ko not_active Expired - Fee Related
- 2010-04-16 RU RU2011147374/04A patent/RU2543716C2/ru active
- 2010-04-16 PL PL10715058T patent/PL2421849T3/pl unknown
- 2010-04-16 AU AU2010239522A patent/AU2010239522B2/en not_active Ceased
- 2010-04-16 ES ES13151470.5T patent/ES2635358T3/es active Active
- 2010-04-16 EP EP13151470.5A patent/EP2599778B1/en active Active
- 2010-04-16 EP EP17164740.7A patent/EP3210981B1/en active Active
- 2010-04-16 SG SG2011077765A patent/SG175330A1/en unknown
- 2010-04-16 PT PT107150583T patent/PT2421849E/pt unknown
- 2010-04-16 SM SM20190168T patent/SMT201900168T1/it unknown
- 2010-04-16 SM SM20170305T patent/SMT201700305T1/it unknown
- 2010-04-16 EP EP10715058A patent/EP2421849B1/en active Active
- 2010-04-16 HU HUE13151470A patent/HUE035049T2/en unknown
- 2010-04-16 NZ NZ595850A patent/NZ595850A/xx not_active IP Right Cessation
- 2010-04-16 JP JP2012507275A patent/JP5671006B2/ja not_active Expired - Fee Related
- 2010-04-16 SI SI201031498T patent/SI2599778T1/sl unknown
- 2010-04-16 RU RU2015101032A patent/RU2676686C2/ru active
- 2010-04-16 LT LTEP13151470.5T patent/LT2599778T/lt unknown
- 2010-04-16 PL PL13151470T patent/PL2599778T3/pl unknown
- 2010-04-23 AR ARP100101379A patent/AR076412A1/es active IP Right Grant
- 2010-04-23 TW TW099112926A patent/TWI513693B/zh not_active IP Right Cessation
- 2010-04-23 TW TW104129981A patent/TWI570115B/zh not_active IP Right Cessation
2011
- 2011-10-05 IL IL215554A patent/IL215554A/en active IP Right Grant
- 2011-10-19 CO CO11139777A patent/CO6440584A2/es active IP Right Grant
- 2011-10-21 ZA ZA2011/07743A patent/ZA201107743B/en unknown
- 2011-10-21 CL CL2011002637A patent/CL2011002637A1/es unknown
2012
- 2012-02-08 US US13/369,109 patent/US8551978B2/en not_active Expired - Fee Related
2013
- 2013-06-07 SM SM201300060T patent/SMT201300060B/xx unknown
- 2013-08-12 US US13/964,484 patent/US8816088B2/en not_active Expired - Fee Related
2014
- 2014-07-10 US US14/327,853 patent/US9000173B2/en not_active Expired - Fee Related
- 2014-08-15 JP JP2014165381A patent/JP5965440B2/ja not_active Expired - Fee Related
2015
- 2015-03-04 US US14/638,171 patent/US9394275B2/en not_active Expired - Fee Related
- 2015-05-22 JP JP2015104157A patent/JP2015147807A/ja active Pending
2016
- 2016-06-13 US US15/180,165 patent/US9572802B2/en not_active Expired - Fee Related
- 2016-12-15 US US15/379,673 patent/US9682957B2/en not_active Expired - Fee Related
2017
- 2017-04-26 US US15/497,446 patent/US9771350B2/en not_active Expired - Fee Related
- 2017-05-09 CY CY20171100498T patent/CY1119008T1/el unknown
- 2017-06-26 HR HRP20170960TT patent/HRP20170960T1/hr unknown
- 2017-08-18 US US15/680,323 patent/US9975875B2/en active Active
2018
- 2018-04-23 US US15/959,549 patent/US10138220B1/en not_active Expired - Fee Related
- 2018-10-15 US US16/159,829 patent/US10358433B2/en not_active Expired - Fee Related
2019
- 2019-02-28 CY CY20191100250T patent/CY1121601T1/el unknown
- 2019-03-04 HR HRP20190417TT patent/HRP20190417T1/hr unknown
- 2019-06-07 US US16/434,220 patent/US10590107B2/en not_active Expired - Fee Related
2020
- 2020-01-28 US US16/774,024 patent/US10836744B2/en not_active Expired - Fee Related
- 2020-10-08 US US17/065,689 patent/US20210024493A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US10358433B2 (en)	2019-07-23
AU2010239522A1 (en)	2011-11-10
DK2599778T3 (en)	2017-06-26
US9975875B2 (en)	2018-05-22
JP2014210816A (ja)	2014-11-13
US20160361304A1 (en)	2016-12-15
US20170226082A1 (en)	2017-08-10
PT3210981T (pt)	2019-04-01
EP2599778A1 (en)	2013-06-05
IL215554A (en)	2014-08-31
US9000173B2 (en)	2015-04-07
TR201903556T4 (tr)	2019-04-22
CN103936716A (zh)	2014-07-23
PT2599778T (pt)	2017-06-06
CY1119008T1 (el)	2018-01-10
US9682957B2 (en)	2017-06-20
SI3210981T1 (sl)	2019-05-31
US9771350B2 (en)	2017-09-26
EP3210981B1 (en)	2019-01-02
CY1121601T1 (el)	2020-05-29
LT3210981T (lt)	2019-04-10
US20150274697A1 (en)	2015-10-01
SI2421849T1 (sl)	2013-07-31
TW201041866A (en)	2010-12-01
HUE042975T2 (hu)	2019-07-29
RU2543716C2 (ru)	2015-03-10
US20130331364A1 (en)	2013-12-12
CN102405218B (zh)	2014-06-04
HRP20170960T1 (hr)	2017-09-22
US20210024493A1 (en)	2021-01-28
US8551978B2 (en)	2013-10-08
EP2421849A1 (en)	2012-02-29
CA2758505C (en)	2017-03-07
US9394275B2 (en)	2016-07-19
US8138345B2 (en)	2012-03-20
BRPI1014877B8 (pt)	2021-05-25
WO2010123766A1 (en)	2010-10-28
AU2010239522B2 (en)	2015-07-02
SG175330A1 (en)	2011-11-28
HK1165799A1 (en)	2012-10-12
US8816088B2 (en)	2014-08-26
US9572802B2 (en)	2017-02-21
US20200165223A1 (en)	2020-05-28
EP2599778B1 (en)	2017-04-12
TWI513693B (zh)	2015-12-21
RU2011147374A (ru)	2013-05-27
BRPI1014877A8 (pt)	2018-03-13
RU2015101032A (ru)	2015-06-27
MY158339A (en)	2016-09-30
CL2011002637A1 (es)	2012-04-27
US20170362200A1 (en)	2017-12-21
BRPI1014877B1 (pt)	2020-11-10
ES2417339T3 (es)	2013-08-07
KR20110138292A (ko)	2011-12-26
MX2011011156A (es)	2011-11-04
PL2421849T3 (pl)	2013-08-30
JP5965440B2 (ja)	2016-08-03
ES2635358T3 (es)	2017-10-03
SMT201900168T1 (it)	2019-05-10
TWI570115B (zh)	2017-02-11
PL2599778T3 (pl)	2018-01-31
US10138220B1 (en)	2018-11-27
HRP20190417T1 (hr)	2019-04-19
CN103936716B (zh)	2016-09-07
US20170096412A1 (en)	2017-04-06
JP2012524783A (ja)	2012-10-18
US20190300504A1 (en)	2019-10-03
HUE035049T2 (en)	2018-05-02
US20130137665A1 (en)	2013-05-30
DK2421849T3 (da)	2013-07-01
JP2015147807A (ja)	2015-08-20
US10590107B2 (en)	2020-03-17
SMT201300060B (it)	2013-07-09
US20190047984A1 (en)	2019-02-14
BRPI1014877A2 (pt)	2016-04-12
KR101769061B1 (ko)	2017-08-17
CO6440584A2 (es)	2012-05-15
NZ595850A (en)	2013-05-31
EP3210981A1 (en)	2017-08-30
JP5671006B2 (ja)	2015-02-18
DK3210981T3 (en)	2019-04-01
HRP20130468T1 (en)	2013-06-30
PT2421849E (pt)	2013-05-27
RU2015101032A3 (lt)	2018-07-30
AR076412A1 (es)	2011-06-08
RU2676686C2 (ru)	2019-01-10
PL3210981T3 (pl)	2019-06-28
ZA201107743B (en)	2012-06-27
EP2421849B1 (en)	2013-04-03
TW201546057A (zh)	2015-12-16
CA2758505A1 (en)	2010-10-28
US20100273755A1 (en)	2010-10-28
IL215554A0 (en)	2011-12-29
ES2715965T3 (es)	2019-06-07
US10836744B2 (en)	2020-11-17
SI2599778T1 (sl)	2017-08-31
SMT201700305T1 (it)	2017-09-07
CN102405218A (zh)	2012-04-04
US20140323733A1 (en)	2014-10-30

Publication	Publication Date	Title
HRP20190417T1 (hr)	2019-04-19	Diamidni spojevi s aktivnošću antagonista muskarinskog receptora i agonista beta 2 adrenergičkog receptora
ZA201309242B (en)	2015-05-27	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP2120575A4 (en)	2011-04-27	AGONISTS AND ANTAGONISTS OF SPHINGOSINE-1-PHOSPHATE RECEPTORS
ZA201202520B (en)	2012-12-27	Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent
IL232478A0 (en)	2014-06-30	New cyclohexylamine derivatives possessing beta 2 adrenergic agonist and m3 muscarinic antagonist activities
IL232477A (en)	2016-11-30	Cyclohexylamine derivatives with the activity of beta 2-adrenergic agonist and 3m muscarinic antagonist
EP2221051A4 (en)	2011-04-27	AMINE DERIVATIVE HAVING ANTAGONIST ACTIVITY OF THE NPY Y5 RECEPTOR AND USE THEREOF
PL2928890T3 (pl)	2018-07-31	Związki wykazujące aktywność antagonisty receptorów muskarynowych i agonisty receptorów beta 2 adrenergicznych
IL219893A0 (en)	2012-07-31	Combinations of a muscarinic receptor antagonist and a beta-2 adrenorecptor agonist
ZA200808817B (en)	2010-03-31	Dialkylphenyl compounds having ß2 adrenergic receptor agonist and muscarinic receptor antagonist activity
ZA201503965B (en)	2016-09-28	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
KR20180085068A (ko)	2018-07-25	무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물
ZA200903873B (en)	2010-10-27	Sphingosine-1-phosphate receptor agonist and antagonist compounds